CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.89 USD | +1.49% |
|
+3.67% | -10.72% |
| 04-18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
| 04-17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR THERAPEUTICS AG | Other Biotechnology & Medical Research | +1.49% | +3.67% | -10.72% | +13.62% | +37.76% | 4.74B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CRSP Stock
- Charts CRISPR Therapeutics AG
- Comparison Chart
